Background Venetoclax plus obinutuzumab has been established as a fixed-duration
treatment regimen for patients with chronic lymphocytic leukaemia. We compared the long …

In chronic lymphocytic leukemia (CLL), the median age at diagnosis is 72 years, and most
patients requiring therapy have coexisting medical conditions. Venetoclax is a potent BH3 …

This single-arm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD)
of venetoclax when given with obinutuzumab and its safety and tolerability in patients with …

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …

Background The BCL2 inhibitor venetoclax has shown activity in patients with chronic
lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with …

Background Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the
B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity in …

Background Selective BCL2 inhibition with venetoclax has substantial activity in patients
with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with …

We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in
patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with …

Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …

Background Both continuous therapy with acalabrutinib and fixed-duration therapy with
venetoclax–obinutuzumab are effective for previously untreated chronic lymphocytic …